Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex®, LLC designates this live educational activity for a maximum 12.25 of AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Who Should Attend
This live meeting is intended for gynecologists, oncologists, and other physicians, clinicians, physicians-in-training, and healthcare professionals (including physician assistants and clinical nurse practitioners) involved in the diagnosis and management of gynecologic cancers including ovarian, uterine, and cervical cancers.
Friday, April 27, 2012
10:00 am
Welcome and introduction
10:10 am
Thesis: Cisplatin and pelvic radiation is the standard therapy for locally advanced cervical cancer limited to the pelvis
Pro
Con
11:00 am
Thesis: Cisplatin and paclitaxel is the standard regimen for treating stage IVB or recurrent cervical cancer
Pro
Con
11:50 am
Challenging case presentation and discussion
12:10 pm
Lunch
Session II: Endometrial Cancer
1:10 pm
Thesis: Lymphadenectomy should be standard in patients with endometrial cancer with any suspected myometrial invasion
Pro
Con
2:00 pm
Thesis: The optimal regimen in the treatment of multifocal recurrent endometrial cancer is carboplatin/paclitaxel
Pro
Con
2:50 pm
Challenging case presentation and discussion
3:10 pm
Break
Session III: Tumor Board
3:30 pm
Case presentation and expert discussion
- Uterine carcinosarcoma
- Leiomyosarcomas of the uterus
- Trophoblastic disease
- Ovarian germ cell tumor
- Granulosa cell tumor of the ovary
5:30 pm
Closing notes and adjourn
Saturday, April 28, 2012
Session IV: Ovarian Cancer
8:00 am
Welcome and introduction
8:10 am
Keynote Address: Molecular biology of ovarian cancer
9:00 am
Beyond bevacizumab: Update on antiangiogenic and vascular disrupting agents
9:30 am
Folate receptor and PARP as a therapeutic target
10:00 am
Clinical utility of cytotoxic agents
10:30 am
Break
10:50 am
Thesis: The systemic treatment of choice for patients with platinum-sensitive recurrent ovarian carcinoma (defined as having achieved a clinical complete response to initial platinum-based therapy and having recurred more than six months after completion of initial treatment) is the following:
Single agent carboplatin
Carboplatin-based doublet (carboplatin plus either PLD, gemcitabine, or paclitaxel)
Carboplatin-based doublet (carboplatin plus either PLD, gemcitabine, or paclitaxel) plus bevacizumab followed by bevacizumab maintenance
11:55 am
Lunch
1:00 pm
Thesis: Paclitaxel plus carboplatin plus bevacizumab followed by bevacizumab maintenance is the systemic treatment of choice for patients with newly diagnosed advanced ovarian carcinoma
Pro
Con
1:50 pm
Thesis: Patients with newly diagnosed advanced ovarian carcinoma, unless surgery is contraindicated medically, should undergo an aggressive attempt at surgical bulk reduction before receiving any systemic treatment (chemotherapy or biologic therapy)
Pro
Con
2:40 pm
Closing notes
2:45 pm
Adjourn
Early
Payment received by February 27, 2012 |
$150.00 |
Discounted
Payment received by April 19, 2012 |
$200.00 |
Regular
If payment received after April 19, 2012 |
$250.00 |
GROUP WITH DISCOUNTED FEES:
Nurses/Students/Residents*
*Proof of eligibility must accompany registration; cannot be combined with any other discounts. |
$99.00 |
To Register: You may register online by April 19, 2012, by emailing Imedex at registration@imedex.com, or by calling Imedex at +1 (855) 276 6855. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Payment: To pre-register, registration and payment must be received no later than April 19, 2012. Please register onsite after this date. Contact Imedex at +1 (855) 276 6855 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full.
Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at customerservice@imedex.com no later than April 19, 2012. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 19, 2012.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
Great Debates and Updates in Gynecologic Malignancies will offer you expert insight into the management of patients with gynecological cancers. Using didactic presentations in conjunction with lively and instructive debates, this comprehensive conference will give practicing clinicians a thorough analysis of all currently available and emerging data.
Conference topics and features:
- Newly diagnosed ovarian cancer
- Lively debates
- Advanced ovarian cancer
- Case presentations
- Gynecologic oncology updates
Comments from 2011 conference attendees:
“The program was just excellent and brought me up to date with managing patients with ovarian cancer.”
“I thoroughly enjoyed the meeting.”
“All the speakers were top-notch and delivered the lectures well.”
Audience Participation... A Hands-On Experience
During the scientific sessions, speakers and the audience can exchange information through a "hands-on" computerized speaker-audience interaction system. With this state-of-the-art equipment, participants answer multiple choice questions, and within seconds, the answers are calculated and projected on a screen in tabular or graphic form for all to see. This system maximizes the ability for attendees from diverse disciplines to see differing opinions and compare consensus between the speakers and each other.
Organizer
Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
For registration inquiries:
Tel.: +1 855-276-6855
Email: registration@imedex.com
Co-Chairs:
Thomas Herzog, MD
Columbia University
Medical Center
New York, New York
Bradley J. Monk, MD
Creighton University
School of Medicine at
St. Joseph’s Hospital and
Medical Center
Phoenix, Arizona
James Thigpen, MD
University of Mississippi
Medical Center
Jackson, Mississippi
Important Dates
Early Registration Deadline
February 27, 2012
Discounted Registration Deadline
April 19, 2012
Presentation Dates
Aril 27-28, 2012
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2011 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
Information coming soon.
Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.
Exhibit space is available to companies interested in participating in this conference through exhibition. For more information, please contact Imedex at +1 (678) 242 0719 or by email at exhibits@imedex.com.
